PDCD1 and non-small cell lung carcinoma: A total of 67 patients with treatment-refractory advanced NSCLC who received anlotinib (another antiangiogenic TKI similar to apatinib) plus PD-1 blockades were included in their retrospective study, and almost all the baseline characteristic subgroup failed to confer a positive association with the PFS of anlotinib plus PD-1 inhibitor administration.